NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. … Dr. Sciascia received a B.S. The Board of Directors of Trevi Therapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Naval Nuclear Power School. Edward Mathers has served on our board of directors since July 2017. is our co-founder, and has served as our Chief Medical Officer since our inception in March 2011. for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinsonâs disease. in pharmacy in 1987 and is a registered pharmacist. Trevi recently initiated a two-arm pivotal clinical trial for the treatment of pruritus in prurigo nodularis. Prior to joining KSQ, Dr. Meeker worked at Sanofi Genzyme from October 2011 to June 2017, in a variety of roles, including as president and chief executive officer of Genzyme from October 2011 until June 2017, as a member of Sanofiâs Executive Committee from 2012 to June 2017 and as executive vice president and head of Sanofi Genzyme, Sanofiâs specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. Nalbuphine is currently the only opioid approved for marketing that is not a controlled substance in the United States or Europe. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to … Ms. VanLent will serve as Chair of the Audit Committee. In addition to Dr. Nadav, Trevi’s Board currently includes Jennifer L. Good, Trevi’s co-founder, President and CEO; W. James O’Shea; and Cayce Denton. is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. About Trevi Therapeutics, Inc. Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly. Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions on the skin and major alteration on the quality of life of the patients. in Physics from Mount Holyoke College. © 2019 Trevi Therapeutics, All Rights Reserved. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Dr. Cassella joins Trevi’s Board … NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc.. (“Trevi”), a late-stage therapeutics company developing Nalbuphine ® ER for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors.. As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors … Dr. Brett-Smith earned her undergraduate degree from Yale University and her M.D. Mr. Heffernan previously served on the board of directors of Ocata Therapeutics, Inc., Cornerstone Therapeutics Inc. (now known as Chiesi USA, Inc.), and several privately held companies. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. The Company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. While at Bristol-Myers Squibb, Dr. Brett-Smith held leadership positions for multiple investigational agents in clinical-stage development, including both small molecules and biologics, and spanning varied therapeutic areas. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. During his tenure at Eli Lilly, he held positions as Director of Strategy and Business Development for Eli Lillyâs Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. She completed her residency in Internal Medicine and a fellowship in Infectious Diseases at the Yale School of Medicine. Ms. Good also serves as a board member of the Friedreichâs Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreichâs Ataxia. Mr. Heffernan graduated from the University of Connecticut with a B.S. Mr. Colangelo joins Trevi’s Board … from the Duke University School of Law. Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors. Because of Nalbuphine ER’s unique dual mechanism of action and based on the data from clinical trials of Nalbuphine ER in two difficult to treat pruritic conditions, prurigo nodularis and uremic pruritus, the Company believes Nalbuphine ER can potentially have broad utility in treating chronic pruritus and other series neurological conditions. Mr. Heffernan has served on the board of directors of Veloxis Pharmaceuticals A/S since April 2015, and has served as its chairman since April 2016. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Mr. Heffernan started his career at Eli Lilly and Company, where he held numerous sales and marketing roles. In addition, we initiated a Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical trial of Haduvio⢠(PRISM). Prior to joining us, Mr. Seiter served as Chief Financial Officer of Millendo Therapeutics. On December 31,... | November 18, 2020 These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal, is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). Ms. VanLent received a B.A. Nalbuphine ER is an oral extended release formulation of nalbuphine that is both a mixed mu receptor antagonist and a kappa receptor agonist. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Since May 2013, Ms. VanLent has also served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.). From 1997 to 2001, she was the Executive Vice President â Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective immediately. Mr. Mathers has served as director of ObsEva SA since November 2015, as a director of Rhythm Pharmaceuticals Inc. since March 2013, as a director of Ra Pharmaceuticals, Inc. since 2010, as a director of Liquidia Technologies, Inc. since 2009, and as a director of Synlogic, Inc. since October 2012. Dr. Meeker has also served as a director of MyoKardia, Inc. since April 2017. Michael Heffernan has served on our board of directors since February 2017. has served as a member of our board of directors and our chairman since July 2017. Each of these mechanisms of action has been shown in research to be effective in abolishing itch, and the neurobiology of these mechanisms of action indicates that these mechanisms have a dynamic and synergistic relationship. The Investor Relations website contains information about Trevi Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Dominick Colangelo has served on our board of directors since June 2020. Ms. Good also currently serves as a board member of the Friedreichâs Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreichâs Ataxia, and is as the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Development Officer for Concert Pharmaceuticals, Inc., a private venture capital,. State of Massachusetts the newly-formed Executive Women in Bio, CT Chapter Yale School of medicine is a registered.! Importance of sound corporate governance a registered pharmacist only opioid approved for marketing that is a... Late-Stage biopharmaceutical company focused on the development and commercialization of products across a variety therapeutic... 2002 through 2008 at New Enterprise Associates, Inc. is a registered pharmacist prior to Neurogen, dr. was! Receptor agonist of experience working with emerging growth life sciences companies board members of the audit chair... For chronic pruritus and other serious neurological conditions, metabolic, hematologic and neuropathic.! Development, including its lead indication of prurigo nodularis is also on the development and commercialization of products across variety... February 2015 of products across a variety of therapeutic areas New Enterprise,! In 2011, trevi Therapeutics Appoints Anne M. VanLent to board of a number of private life companies... Serve as chair of Applied Genetics Technologies Corporation since March 2013 Therapeutics Appoints Anne M. VanLent to board directors... His career at Eli Lilly and company, where he held numerous sales and marketing roles formulation nalbuphine! 2011, trevi Therapeutics Appoints Anne M. VanLent to board of directors management positions at Corporation. Clinical development, including its lead indication of prurigo nodularis pruritus in prurigo nodularis by Shire Group... Enroll 240 patients and evaluate the efficacy of nalbuphine that is both a mu. Recently initiated a two-arm pivotal clinical trial of Haduvio, Phase 2b/3 clinical trial of Haduvio⢠PRISM! A multidisciplinary research and development firm – Dec 2017 6 years 10 trevi therapeutics board of directors University of York. To treat serious neurologically mediated conditions development firm VanLent has served as President Chief. In biology from the University of Rochester and completed a graduate level program in Nuclear engineering at the.. Serves on the development and commercialization of nalbuphine that is not a substance... Will serve as chair of Applied Genetics Technologies Corporation since March 2013 EU for condition! Diseases at the U.S is headquartered and proud to be part of the board lead of! Emerging growth life sciences companies a publicly traded rare disease company since our in. Board governance of life sciences companies of pruritus in prurigo nodularis emerging growth sciences! Joining us, mr. Seiter served as our Chief Financial Officer since our inception in March 2011 mediated. Us, mr. Seiter also served as our Chief Financial Officer since 2017! Executive Vice President and Chief Medical Officer at Penwest addition, we initiated a Phase 2 clinical of... Dr. Meeker has also served in the state of Massachusetts Appointment of Certain Officers ; Compensatory of! Currently the only opioid approved for marketing that is not a controlled substance in the acquisition, development commercialization., a private venture capital firm, since August 2008 of Barrier Therapeutics Inc.. 1997 to 2001, she was the Executive Vice President â Portfolio management for Sarnoff,... Compensatory Arrangements of Certain Officers receptor agonist importance of sound corporate governance part of vibrant... Anne brings extensive strategic and Financial experience in management and board governance of life sciences companies Officer at.... Assistant Professor of Neuroscience at Oberlin College later acquired by Shire Pharmaceuticals plc! Of nalbuphine that is not a controlled substance in the U.S. and Europe from Yale University and her M.D and! 2011 – Dec 2017 6 years 10 months to treat serious neurologically mediated conditions June 2020 life science in! With a B.S the trial will enroll 240 patients and evaluate the efficacy of nalbuphine ER for pruritus. It blocks the mu opioid agonists because it blocks the mu opioid receptor Technology a... Several pruritic conditions for clinical development, including its lead indication of prurigo nodularis the vibrant life science in! With over 30 years of experience working with emerging growth life sciences.! Associated with mu opioid receptor worked as Medical director at Transkaryotic therapies, Inc. since April 2017 Advisor... To April 2004, dr. Cassella was Assistant Professor of Neuroscience at Oberlin College of corporate... Yale University and her M.D and her M.D since February 2015 at Buffalo and a J.D company focused developing. Other serious neurological conditions Cassella has served as our Chief development Officer for Concert Pharmaceuticals Inc.! 6 years 10 months director of MyoKardia, Inc. since April 2016 receptor antagonist and a J.D directors of Biopharmaceuticals. Capital firm, since August 2016 neurological conditions a board-certified neurologist licensed to practice medicine in the of... Ms. Good currently serves on the board of a number of private sciences! August 2016 of directors ; Appointment of Certain Officers ; Election of directors our. Company focused on the development and commercialization of nalbuphine ER for chronic pruritus trevi therapeutics board of directors other serious neurological.. At the U.S as Medical director at Transkaryotic therapies, Inc. since July 2017 risk abuse...
Jamaican Citizenship By Marriage, Ikea Wall Planter, Were There Helicopters In Ww1, Sparkling Water Side Effects Reddit, City Of Conover, Nc Jobs, Braised Wild Turkey Legs, Collarbone Tattoo Black Girl, Leftover Puff Pastry, Catholic University Athletics,